NCT07123376

Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects

A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study Was Conducted to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of HRS-9231 Injection in a Single Dose in Healthy Chinese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of HRS-9231 injection in a single dose in healthy subjects

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	HRS-9231	HRS-9231 was administered intravenously;
DRUG	Placebo	Placebo was administered intravenously.

Timeline

• Start date: 2024-06-05
• Primary completion: 2024-10-06
• Completion: 2024-10-06
• First posted: 2025-08-14
• Last updated: 2025-08-14

Locations

1 site across 1 country: China